Mobocertinib not checked

Millennium Pharmaceuticals, Inc. · TAK-788 · AP32788

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
None yet
 
Trials
1 active
8 in total

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
Tested for
Non-Small Cell Lung Cancer
Main trialPhase 1
“This study is in 2 parts. Different participants will take part in the 1st and 2nd parts of the study. The main aim of the 1st part of the study is to check how much Mobocertinib adults with non-small cell lung cancer (NSCLC) can receive without getting side effects from it. The main aim of the 2nd part of the study is to learn if the condition of adults with non-small cell lung cancer improves after treatment with Mobocertinib. Another aim is to continue checking for side effects from Mobocertinib. In the 1st part of the study, at the first visit, the study doctor will check who can take…”In the company’s words, NCT03807778 on ClinicalTrials.gov
Other names
TAK-788 · AP32788

Other drugs for Non-Small Cell Lung Cancer

All 560 drugs for Non-Small Cell Lung Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting 8 Nov 2021 A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer
Phase 3Completed 22 Sep 2026 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Phase 1/2Completed 29 Sep 2026 A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Phase 1Completed 11 Mar 2019 A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants
Phase 1Completed 10 Aug 2020 A Study to Evaluate the Effect of High-Fat Meal on TAK-788 Pharmacokinetics (PK) in Healthy Adult Participants
Phase 1Completed 17 Dec 2020 Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 1Completed 5 Feb 2022 A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
Phase 1Completed 20 Apr 2022 A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow Mobocertinib

Following is part of Solo: you see every change to Mobocertinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in